Sight Sciences Inc
NASDAQ:SGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sight Sciences Inc
NASDAQ:SGHT
|
US |
|
Hillenbrand Inc
NYSE:HI
|
US |
|
F
|
Fortune Oriental Co Ltd
TWSE:2491
|
TW |
|
IVS Group SA
MIL:IVS
|
IT |
|
Digital Ally Inc
NASDAQ:DGLY
|
US |
|
Shutterstock Inc
NYSE:SSTK
|
US |
|
M
|
MBC Group CJSC
SAU:4072
|
SA |
|
C
|
Cencora Inc
XBER:ABG
|
US |
|
D
|
Dingyi Group Investment Ltd
HKEX:508
|
HK |
|
Novatek Microelectronics Corp
TWSE:3034
|
TW |
|
Saudi Printing and Packaging Company SJSC
SAU:4270
|
SA |
Sight Sciences Inc
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
